Tesamorelin (Tesamorelin Acetate (Egrifta))
A synthetic GHRH analog FDA-approved for HIV-associated lipodystrophy. Particularly effective at reducing visceral adipose tissue with emerging cognitive benefits.
How it works
Binds pituitary GHRH receptors with enhanced affinity via hexenoic acid modification. Effective at mobilizing visceral fat via GH-mediated lipolysis.
Key facts
- Molecular weight: 5,136 Da
- Half-life: 26-38 minutes
- Bioavailability: High (SubQ)
- Storage: Lyophilized: refrigerated. Reconstituted: use immediately.
Dosing overview
- Typical dose: 2 mg
- Frequency: Once daily
- Duration: 12-26 weeks
- Route: Subcutaneous injection
Protocol notes
- FDA-approved protocol is a fixed 2 mg once daily (no titration needed).
- Inject subcutaneously into the abdomen; effect on visceral fat builds over ~12-26 weeks.
Reported benefits
- Visceral fat reduction (up to 18%)
- FDA-approved safety
- Improved lipid panels
- Cognitive benefits (emerging)
- No significant IGF-1 overshoot
Possible side effects
- Injection site reactions
- Joint pain
- Peripheral edema
- Hyperglycemia
- Pruritus
Research
- Tesamorelin reduces visceral adiposity in HIV patients (2019): Reduced visceral adipose tissue by 18% at 26 weeks with lipid improvements.
- Cognitive effects of tesamorelin in adults at risk for AD (2022): Improved executive function and verbal memory with preserved hippocampal volume vs placebo.
Compare Tesamorelin
Community discussions about Tesamorelin
- Limited-Time Promotion - 0 comments
- Factory Direct With Full After‑Sales Protection - 3 comments
- Tesamorelin and Ipamorelin combo vs just Ipa for sleep and hunger - 4 comments
- China Peptide Source Factory - 3 comments
- Tesamorelin’s VAT loss: promising marker, uncertain performance - 4 comments
- Ask the community about Tesamorelin
Research and educational reference only. Not medical advice.